Michael Christiano
About Michael Christiano
Michael Christiano serves as the Chief Business Officer and a member of the Executive Leadership Team at the Broad Institute of MIT and Harvard. He has extensive experience in business development and strategic partnerships, having held leadership roles at Novartis, Tmunity Therapeutics, and AVEO Oncology.
Current Role at Broad Institute
Michael Christiano serves as the Chief Business Officer and is a member of the Executive Leadership Team at the Broad Institute of MIT and Harvard. He has held this position since 2021, contributing to the institute's strategic direction and partnerships. His responsibilities include leading the office of strategic alliances and partnerships, where he establishes collaborations and forms new companies to advance the Broad's scientific mission. His role involves negotiating transformative license and collaboration agreements, mergers and acquisitions, and early-stage equity investments in the life sciences sector.
Previous Experience at Novartis
Michael Christiano has extensive experience at Novartis, where he held multiple roles over several years. His positions included Executive Director and Head of Transactions for the Cell and Gene Therapies Unit, and Vice President and Head of Transactions for Global Business Development and Licensing. His leadership in transactions was recognized through Novartis's President’s, Innovation, and Team Awards. He played a significant role in establishing innovative transactions across Novartis's oncology and cell and gene portfolios.
Career Background in Business Development
Michael Christiano has a solid background in business development within the life sciences industry. He worked at AVEO Oncology as Director of Business Development and later as Senior Director. His experience also includes serving as Associate Director at Millennium Pharmaceuticals and as Co-Founder of Karyopharm Therapeutics Inc. Additionally, he was a founding management team member at Tmunity Therapeutics, where he contributed to establishing the CAR-T company and developing its product and platform portfolios.
Educational Qualifications
Michael Christiano holds an MBA from Cornell University and a Bachelor of Science in Finance from Virginia Tech. His educational background has equipped him with the necessary skills and knowledge to excel in business development and strategic leadership roles within the life sciences sector.
Notable Contributions and Achievements
Throughout his career, Michael Christiano has made significant contributions to the life sciences industry. He played an instrumental role in the acquisition of Tmunity Therapeutics by Gilead. His expertise in negotiating and establishing strategic partnerships has been vital in advancing the missions of the organizations he has been part of, particularly in oncology and cell and gene therapies.